Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S B Kaye

Showing results (371-380 of 411) with videos related to

Pageof 42
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer studyS B Kaye, G M Mead, S Fossa, et al.
Cancer Research|May 15, 1987
Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Treatment of Cancer Multiinstitutional Phase III StudyG Stoter, R Sylvester, D T Sleijfer, et al.
Progress in Clinical and Biological Research|January 1, 1988
A multivariate analysis of prognostic factors in disseminated non-seminomatous testicular cancerG Stoter, R Sylvester, D T Sleijfer, et al.
International Journal of Andrology|February 1, 1987
Multivariate analysis of prognostic variables in patients with disseminated non-seminomatous testicular cancer: results from an EORTC multi-institutional phase III studyG Stoter, R Sylvester, D T Sleijfer, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. EORTC Genitourinary Tract Cancer Cooperative Group (EORTC GU Group)R L Jansen, R Sylvester, D T Sleyfer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1986
High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative GroupG Stoter, D T Sleyfer, W W ten Bokkel Huinink, et al.
Oncology|August 15, 2012
Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trialsB Basu, J Vitfell-Pedersen, V Moreno Garcia, et al.
British Journal of Cancer|November 21, 1998
Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significanceR de Wit, L Collette, R Sylvester, et al.
British Journal of Cancer|January 13, 2016
Phase I trial outcomes in older patients with advanced solid tumoursK H Khan, T A Yap, A Ring, et al.
British Journal of Cancer|October 27, 2012
Association of creatine kinase and skin toxicity in phase I trials of anticancer agentsV Moreno Garcia, P Thavasu, M Blanco Codesido, et al.
Pageof 42

Showing results (371-380 of 411) with videos related to

Sort By:
Pageof 42
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer studyS B Kaye, G M Mead, S Fossa, et al.
Cancer Research|May 15, 1987
Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Treatment of Cancer Multiinstitutional Phase III StudyG Stoter, R Sylvester, D T Sleijfer, et al.
Progress in Clinical and Biological Research|January 1, 1988
A multivariate analysis of prognostic factors in disseminated non-seminomatous testicular cancerG Stoter, R Sylvester, D T Sleijfer, et al.
International Journal of Andrology|February 1, 1987
Multivariate analysis of prognostic variables in patients with disseminated non-seminomatous testicular cancer: results from an EORTC multi-institutional phase III studyG Stoter, R Sylvester, D T Sleijfer, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. EORTC Genitourinary Tract Cancer Cooperative Group (EORTC GU Group)R L Jansen, R Sylvester, D T Sleyfer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1986
High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative GroupG Stoter, D T Sleyfer, W W ten Bokkel Huinink, et al.
Oncology|August 15, 2012
Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trialsB Basu, J Vitfell-Pedersen, V Moreno Garcia, et al.
British Journal of Cancer|November 21, 1998
Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significanceR de Wit, L Collette, R Sylvester, et al.
British Journal of Cancer|January 13, 2016
Phase I trial outcomes in older patients with advanced solid tumoursK H Khan, T A Yap, A Ring, et al.
British Journal of Cancer|October 27, 2012
Association of creatine kinase and skin toxicity in phase I trials of anticancer agentsV Moreno Garcia, P Thavasu, M Blanco Codesido, et al.
Pageof 42